STOCKHOLM, SE / ACCESS Newswire / October 14, 2025 / AlzeCure Pharma AB (publ) (FN STO:ALZCUR)(STO:ALZCUR)(FRA:AC6), a pharmaceutical company that develops candidate drugs for diseases affecting the ...
BioArctic AB (publ) (NASDAQ Stockholm: BIOA B) announced today that Leqembi has now been made available at a private clinic in Finland and ...
1d
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”
Viehbacher, “Biogen”) announced today that LEQEMBI ® IQLIK™, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer’s disease (AD) has been selected by ...
News-Medical.Net on MSN
Scientists revive diabetic beta cells, revealing a new path to restore insulin function
Researchers demonstrated that pancreatic β cells from type 2 diabetes donors can partially regain glucose responsiveness when ...
Can Pfizer’s GDF15-blocking, appetite-boosting antibody ponsegromab address a cancer-induced wasting syndrome — and help ...
Conjugation is mediated by a large molecular machinery termed Type IV secretion system (T4SS), embedded within the donor cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback